We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GYRO:NASDAQGyrodyne , LLC Analysis

Data as of 2026-05-27 - not real-time

$7.20

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Gyrodyne, LLC is trading at $7.20, well below its 20‑day SMA of 7.52, 50‑day SMA of 7.76 and 200‑day SMA of 9.11, signaling a bearish price trend. The RSI of 29 indicates the stock is oversold, while a bearish MACD histogram reinforces short‑term weakness. Volume is on the rise, suggesting some buying interest near the support level of $6.70, yet the price remains capped by a resistance around $7.96. Fundamental metrics are troubling: operating margins are deeply negative, EBITDA is a loss of over $3 M, and the debt‑to‑equity ratio sits at 69 %, raising solvency concerns. However, the stock’s price‑to‑book of 0.21 reflects a steep discount to its book value of $34.54 per share, and the beta of roughly 0.13 points to low market volatility exposure. The 30‑day volatility of 25 % and a recent max drawdown of 33 % underscore heightened price swings in a thinly traded market (≈$15.8 M cap, avg. volume ~1.3k).
Given the extreme “Greed” sentiment in the Fear & Greed Index (91.6) and the lack of dividend, the upside appears speculative. The company’s concentration in the New York metropolitan real‑estate market adds moderate geographic and regulatory risk, while the low liquidity amplifies execution risk. Investors must weigh the deep asset discount against ongoing losses and debt load when forming a view.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • RSI in oversold territory suggests potential bounce
  • Price hovering just above key support at $6.70
  • Increasing trading volume indicating renewed interest

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Sustained negative earnings and cash flow
  • High debt‑to‑equity ratio limiting financial flexibility
  • Bearish MACD and price below all major moving averages

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant discount to book value (P/B ~0.21)
  • Potential value creation from entitlement and redevelopment projects in NY
  • Low beta indicating limited market‑wide volatility exposure

Key Metrics & Analysis

Financial Health

Revenue Growth-1.80%
Profit Margin-137.05%
P/E Ratio45.0
Debt/Equity69.24
P/B Ratio0.2
Op. Cash Flow$-3440937
Industry P/E32.8

Technical Analysis

TrendBearish
RSI29.2
Support$6.70
Resistance$7.96
MA 20$7.52
MA 50$7.76
MA 200$9.11
MACDBearish
VolumeIncreasing
Fear & Greed Index91.57

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.13
Volatility25.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.